BETHESDA, Md., Oct. 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, November 6, 2008, at 9:00 am Eastern Time (3:00 pm Central European Time) to discuss its third quarter 2008 financial results. Micromet anticipates releasing its financial results at 7:00 am Eastern Time (1:00 pm Central European Time) on Thursday, November 6, 2008.
To participate in this conference call, dial 800-299-0148 (U.S.) or 617-801-9711 (international), passcode: 70506651. The audio webcast can be accessed at: http://www.micromet-inc.com in the investor relations section of the website.
A replay of the call will be available from 12:00 pm Eastern Time on November 6, 2008 (6:00 pm Central European Time) through Thursday, November 13, 2008. The replay number is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 99269687.
About Micromet, Inc.
Micromet, Inc. (http://www.micromet-inc.com) is a biopharmaceutical company
developing novel, proprietary antibodies for the treatment of cancer,
inflammation and autoimmune diseases. Four of its antibodies are currently
in clinical trials, while the remainder of the product pipeline is in
preclinical development. The BiTE(R) antibody blinatumomab (MT103/MEDI-538)
is in a phase 2 clinical trial for the treatment of patients with acute
lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of
patients with non-Hodgkin's lymphoma. BiTE
|SOURCE Micromet, Inc.|
Copyright©2008 PR Newswire.
All rights reserved